ArticleInternational journal of molecular sciences2026
Phenotypic Complexity and Diagnostic Utility of Exome Sequencing in ASD: Real-World Insights from Colombia.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism spectrum disorder (ASD) is a genetically heterogeneous condition; however, genomic data from Latin American populations remain limited. We investigated the molecular and phenotypic landscape of ASD in 916 Colombian patients who underwent whole-exome sequencing (WES) between 2022 and 2025. Clinical and genomic data were retrospectively analyzed, and phenotypes were standardized using Human Phenotype Ontology (HPO) terms. Variants were classified per ACMG/ClinGen guidelines, and we assessed phenotypic burden, predictors of molecular diagnosis, copy number variants (CNVs), and functional convergence of candidate genes. A molecular diagnosis was identified in 112 patients (12.2%), including 82 with variants in ASD-associated genes or regions and 30 with findings related to other clinical features. We identified 16 novel pathogenic/likely pathogenic variants, along with 10 CNVs. Among trio-based patients, 70.9% of molecular diagnoses were de novo. Higher phenotypic burden was associated with molecular diagnosis, and global developmental delay was the strongest predictor after correction for multiple testing. Functional enrichment analysis of candidate genes showed convergence on pathways related to neuronal development, synaptic function, and ion transport. These findings highlight the genetic and phenotypic heterogeneity of ASD and support the value of integrating standardized genomic and phenotypic characterization in Colombian populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.